🇺🇸 Flixotide in United States

999 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Asthma — 167 reports (16.72%)
  2. Dyspnoea — 164 reports (16.42%)
  3. Drug Ineffective — 123 reports (12.31%)
  4. Cough — 99 reports (9.91%)
  5. Pyrexia — 80 reports (8.01%)
  6. Fatigue — 77 reports (7.71%)
  7. Pneumonia — 77 reports (7.71%)
  8. Asthmatic Crisis — 73 reports (7.31%)
  9. Malaise — 71 reports (7.11%)
  10. Off Label Use — 68 reports (6.81%)

Source database →

Flixotide in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is Flixotide approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Flixotide in United States?

Mundipharma Research Limited is the originator. The local marketing authorisation holder may differ — check the official source linked above.